Find and Pitch Jounalists, Get Your Story Covered

Tags: gear reviews Gaming shopping video games

	Profile	Recent Articles on Subject
1	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy - 26 days ago Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - 3 months ago J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer - 7 months ago Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials - 8 months ago J&J-Partnered Contineum Corrals $110M From IPO for Clinical Trials in Fibrosis & MS - 8 months ago
2	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more - 9 months ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - 10 months ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 11 months ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - 11 months ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - 12 months ago STAT+: Pharmalittle: Bluebird’s sickle-cell screwups may prompt a sale; drugmakers raised prices on widely used meds without new clinical evidence - 12 months ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - 12 months ago STAT+: Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines - about 1 year ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - about 1 year ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	More evidence on GLP-1s and opioid addiction - about 1 month ago
4	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - about 2 months ago Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category - 9 months ago Astellas’ science chief on the leap into new technologies - 10 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 11 months ago
5	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Simon Jones - 3 months ago
6	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors - 4 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 4 months ago Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder - 4 months ago Black Diamond looks to outwit cancer mutations - 9 months ago
7	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more - 4 months ago STAT+: Vertex non-opioid drug reduces chronic nerve pain in mid-stage study - 12 months ago STAT+: Inside Vertex’s decades-long quest to develop a new class of non-opioid painkillers - 12 months ago
8	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies - 4 months ago STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund - 4 months ago STAT+: Investors funnel $275 million into Paragon Therapeutics spinout - 8 months ago STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - 9 months ago STAT+: Biotech launches with $135 million for Vertex-competing pain medicine - 9 months ago STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk - 12 months ago STAT+: Biotech incubator Curie.Bio graduates its first startup - about 1 year ago
9	Michael Nuñez VentureBeat Editorial Director at VentureBeat. San Francisco editorial directiontechnology news	McKesson, Merck back Atropos Health’s $33M round to accelerate drug development with AI - 6 months ago
10	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more - 6 months ago STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act - 9 months ago

Journalists covering Curve Therapeutics